Advisory panel to consider risks of possible OTC cholesterol drug

01/13/2005 |

The FDA wants an advisory panel to consider potential risks of people taking large doses of Merck's cholesterol drug Mevacor, which the company wants to sell over the counter. Some FDA staff members say the drug offers benefits if taken properly, but want the review panel, scheduled to meet today and tomorrow, to consider possible risks from higher doses. Medical experts differ on the proposal, with some saying easier access to statins would help curb heart disease, while others say possible side effects should be monitored by doctors.

View Full Article in:

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Senior Counsel – Regulatory Affairs
RAI Services Company
Winston-Salem, NC